In response to the Federal Trade Commission’s decision to expand its jurisdiction over approving different types of exclusive pharmaceutical patent rights licenses, Pharmaceutical Research and Manufacturers of America has accused the FTC of exceeding its authority. Additionally, PhRMA has called for the FTC to dismiss the decision, arguing it discriminates against the pharmaceutical industry, and has asked the authority to change its premerger notification rules.
Featured News
South Korea Expands Food Price-Fixing Probe to Four Major Instant Noodle Makers
Oct 28, 2026 by
CPI
Biden’s Former Antitrust Chiefs Launch AI Legal Startup FluxCap
Oct 28, 2026 by
CPI
NBA Teams Up With US Regulator on Prediction Markets
Oct 27, 2026 by
CPI
Intesa Wins ECB Approval for $36 Billion Monte dei Paschi Takeover
Oct 27, 2026 by
CPI
PayPal, Revolut Weigh In as UK Targets Apple’s Tap-to-Pay Rules
Oct 27, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI